FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1844779080> ?p ?o ?g. }

• W1844779080 endingPage "8" @default.
• W1844779080 startingPage "1080" @default.
• W1844779080 abstract "The response to hepatitis B vaccine in the dialysis population is reduced compared to the general population. The intradermal (ID) hepatitis B vaccine has been studied as a potential alternative to intramuscular (IM) administration. This alternative route of administration may illicit a response via a distinct immunologic pathway that may help achieve higher seroconversion rates and thus, protection against hepatitis B infection in this vulnerable patient population.A literature search was performed in January 2015 using Embase, MEDLINE, and the Cochrane Central Register of Controlled Trials with keywords including, hepatitis B vaccines, intradermal, dermal, intracutaneous, dialysis, hemodialysis, continuous ambulatory peritoneal dialysis, CAPD, peritoneal dialysis, renal failure, chronic renal failure, chronic kidney disease, chronic renal insufficiency, End Stage Renal Disease, ESRD, and CKD. Our search strategy was restricted to human studies published in the English language, and additional literature was retrieved by hand-searching bibliographies of relevant articles. Two reviewers (F.Y. and S.G.) independently reviewed abstracts and/or full texts of articles retrieved from the electronic database using the above-mentioned search strategy. Inclusion criteria were as follows: (1) Published, English-language studies performed in the human population, (2) adult patient population (≥18 years of age), (3) randomized trials, (4) patient population must have been unresponsive to a primary IM hepatitis B vaccination protocol, (5) patients must be chronic dialysis patients, either on maintenance hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), (6) studies that compare IM and ID hepatitis B vaccination-associated seroconversion rates, (7) results must be reported as seroconversion rates at 1-3, 6-9, 12, or 20 months post-vaccination, and (8) seroconversion (protective antibody levels) defined as >10 or ≥10 IU/L.Our initial literature review yielded 113 results, of which four were included in our final review. These four prospective trials studied a combined total of 204 dialysis patients. Of these patients, 120 (59%) had received the hepatitis B vaccine intradermally, while 84 (41%) received it intramuscularly. Hepatitis B vaccination type, dose, route, and seroconversion rates were tabulated for each study. Each of the studies used different protocols for patient inclusion, schedule of vaccine administration, and time-points for measuring seroconversion. Seroconversion rates at either 1, 2, 3, 6-9, 12 and/or 20 months were reported. The combined seroconversion rates were 91%, 83%, 86%, 81%, 76%, and 32% at 1, 2, 3, 6-9, 12, and 20 months in the ID group, respectively, and 55%, 72%, 58%, 44%, 24%, and 0% in the IM group, respectively. Chi-square analysis revealed a significantly higher proportion of patients achieving seroconversion in the ID group versus the IM group (p < 0.05).Our review demonstrates that ID hepatitis B vaccination in primary non-responders undergoing dialysis provides an effective alternative to IM vaccination as a means of protection against hepatitis B infection in this highly susceptible population. Additional well-designed, double-blinded, randomized trials are warranted to establish clear guidelines on ID Hepatitis B vaccine dose and duration of vaccination schedule." @default.
• W1844779080 created "2016-06-24" @default.
• W1844779080 creator A5021193745 @default.
• W1844779080 creator A5044213881 @default.
• W1844779080 creator A5053513287 @default.
• W1844779080 creator A5079649665 @default.
• W1844779080 creator A5091311236 @default.
• W1844779080 date "2015-08-01" @default.
• W1844779080 modified "2023-09-23" @default.
• W1844779080 title "Systematic review of the efficacy and safety of intradermal versus intramuscular hepatitis B vaccination in end-stage renal disease population unresponsive to primary vaccination series." @default.
• W1844779080 cites W1436849262 @default.
• W1844779080 cites W1905697899 @default.
• W1844779080 cites W1918817725 @default.
• W1844779080 cites W1968283974 @default.
• W1844779080 cites W1981380496 @default.
• W1844779080 cites W1992127959 @default.
• W1844779080 cites W1992178241 @default.
• W1844779080 cites W2010294715 @default.
• W1844779080 cites W2011932878 @default.
• W1844779080 cites W2019961175 @default.
• W1844779080 cites W2037318190 @default.
• W1844779080 cites W2081114166 @default.
• W1844779080 cites W2083320916 @default.
• W1844779080 cites W2083663054 @default.
• W1844779080 cites W2084217571 @default.
• W1844779080 cites W2113740195 @default.
• W1844779080 cites W2143100608 @default.
• W1844779080 cites W2146292357 @default.
• W1844779080 cites W2149821903 @default.
• W1844779080 cites W2163279438 @default.
• W1844779080 cites W2411547516 @default.
• W1844779080 cites W2414914418 @default.
• W1844779080 cites W2460539353 @default.
• W1844779080 cites W2905642084 @default.
• W1844779080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26258528" @default.
• W1844779080 hasPublicationYear "2015" @default.
• W1844779080 type Work @default.
• W1844779080 sameAs 1844779080 @default.
• W1844779080 citedByCount "4" @default.
• W1844779080 countsByYear W18447790802016 @default.
• W1844779080 countsByYear W18447790802018 @default.
• W1844779080 countsByYear W18447790802019 @default.
• W1844779080 countsByYear W18447790802022 @default.
• W1844779080 crossrefType "journal-article" @default.
• W1844779080 hasAuthorship W1844779080A5021193745 @default.
• W1844779080 hasAuthorship W1844779080A5044213881 @default.
• W1844779080 hasAuthorship W1844779080A5053513287 @default.
• W1844779080 hasAuthorship W1844779080A5079649665 @default.
• W1844779080 hasAuthorship W1844779080A5091311236 @default.
• W1844779080 hasConcept C126322002 @default.
• W1844779080 hasConcept C203014093 @default.
• W1844779080 hasConcept C2522874641 @default.
• W1844779080 hasConcept C2777382497 @default.
• W1844779080 hasConcept C2777410769 @default.
• W1844779080 hasConcept C2777451964 @default.
• W1844779080 hasConcept C2778063415 @default.
• W1844779080 hasConcept C2778653478 @default.
• W1844779080 hasConcept C2779056158 @default.
• W1844779080 hasConcept C2779978075 @default.
• W1844779080 hasConcept C2780593183 @default.
• W1844779080 hasConcept C2781037505 @default.
• W1844779080 hasConcept C2908647359 @default.
• W1844779080 hasConcept C2909406889 @default.
• W1844779080 hasConcept C3019040382 @default.
• W1844779080 hasConcept C71924100 @default.
• W1844779080 hasConcept C99454951 @default.
• W1844779080 hasConceptScore W1844779080C126322002 @default.
• W1844779080 hasConceptScore W1844779080C203014093 @default.
• W1844779080 hasConceptScore W1844779080C2522874641 @default.
• W1844779080 hasConceptScore W1844779080C2777382497 @default.
• W1844779080 hasConceptScore W1844779080C2777410769 @default.
• W1844779080 hasConceptScore W1844779080C2777451964 @default.
• W1844779080 hasConceptScore W1844779080C2778063415 @default.
• W1844779080 hasConceptScore W1844779080C2778653478 @default.
• W1844779080 hasConceptScore W1844779080C2779056158 @default.
• W1844779080 hasConceptScore W1844779080C2779978075 @default.
• W1844779080 hasConceptScore W1844779080C2780593183 @default.
• W1844779080 hasConceptScore W1844779080C2781037505 @default.
• W1844779080 hasConceptScore W1844779080C2908647359 @default.
• W1844779080 hasConceptScore W1844779080C2909406889 @default.
• W1844779080 hasConceptScore W1844779080C3019040382 @default.
• W1844779080 hasConceptScore W1844779080C71924100 @default.
• W1844779080 hasConceptScore W1844779080C99454951 @default.
• W1844779080 hasIssue "7" @default.
• W1844779080 hasLocation W18447790801 @default.
• W1844779080 hasOpenAccess W1844779080 @default.
• W1844779080 hasPrimaryLocation W18447790801 @default.
• W1844779080 hasRelatedWork W1994440358 @default.
• W1844779080 hasRelatedWork W2129208268 @default.
• W1844779080 hasRelatedWork W2259896879 @default.
• W1844779080 hasRelatedWork W2331223368 @default.
• W1844779080 hasRelatedWork W2395974705 @default.
• W1844779080 hasRelatedWork W2411167357 @default.
• W1844779080 hasRelatedWork W2412813449 @default.
• W1844779080 hasRelatedWork W279429541 @default.
• W1844779080 hasRelatedWork W3030569160 @default.
• W1844779080 hasRelatedWork W973253908 @default.
• W1844779080 hasVolume "37" @default.

• next